Stock ACHL ACHILLES THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-04-29 EDT 		5-day change 1st Jan Change
0.76 USD 0.00% Intraday chart for Achilles Therapeutics plc -3.80% -14.51%
04-05 Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8 MT
04-05 Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating MT

Evolution of the average Target Price on Achilles Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

7e97198486d7848f3a8662ad4b5c7dd.PkFM-3KGoegTzrWqIlYdo7hxwQO_ZHpWaMRUoIyq54M.TyB0zzGx06pZvdPDVxxo79MpkknOVkoiD4sQ0-3-vbNPcDmWEfPvnXa_5A~c2d79d054a7e2efefe5a2b503dc0ffe7

Analyst Recommendations on Achilles Therapeutics plc

Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8 MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating MT
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50 MT
Chardan Trims Price Target on Achilles Therapeutics to $11 From $12, Keeps Buy Rating MT
Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating MT
Oppenheimer Downgrades Achilles Therapeutics to Perform From Outperform on Lack of Clear Benefits to Cancer Drug Over Peer Treatment, Removes PT From $19 MT
Piper Sandler Cuts Price Target on Achilles Therapeutics to $8 From $10, Keeps Overweight Rating MT
Chardan Cuts Price Target on Achilles Therapeutics to $17 From $20, Affirms Buy Rating MT
Piper Sandler Adjusts Price Target on Achilles Therapeutics to $10 From $17, Reiterates Overweight Rating MT
Oppenheimer Adjusts Achilles Therapeutics Price Target to $19 From $23, Maintains Outperform Rating MT
ACHILLES THERAPEUTICS : JP Morgan Initiates Achilles Therapeutics at Underweight Rating With $11 Price Target MT
ACHILLES THERAPEUTICS : Oppenheimer Initiates Coverage on Achilles Therapeutics With Outperform Rating, $23 Price Target MT
ACHILLES THERAPEUTICS : Chardan Initiates Coverage on Achilles Therapeutics With Buy Rating, $27 Price Target MT
ACHILLES THERAPEUTICS : BofA Securities Starts Achilles Therapeutics at Buy With $20 Price Target MT
ACHILLES THERAPEUTICS : Piper Sandler Starts Achilles Therapeutics at Overweight With $25 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.76 USD
Average target price
4.125 USD
Spread / Average Target
+442.76%
High Price Target
8 USD
Spread / Highest target
+952.63%
Low Price Target
0.5 USD
Spread / Lowest Target
-34.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Achilles Therapeutics plc

Chardan Research
Piper Sandler
BofA Securities
Oppenheimer
Chardan
J.P. Morgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ACHL Stock
  4. Consensus Achilles Therapeutics plc